Trial Profile

A Phase II Study of VP-103 in Subjects with Plantar Warts

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cantharidin (Primary)
Indications Warts
Focus Therapeutic Use
Sponsors Verrica Pharmaceuticals

Most Recent Events

27 May 2020 According to a Verrica Pharmaceuticals media release, the company is conducting necessary preclinical activities for VP-103 and, in light of the COVID-19 pandemic, intends to launch this Phase 2 clinical trial in subjects with plantar warts when conditions are appropriate.
31 Mar 2020 New trial record
13 Mar 2020 According to a Verrica Pharmaceuticals media release, the company intends to start this trial at least through the second quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com